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The regulating mechanism of miRNA on p53 dynamics in p53−MDM2−miRNA model network
incorporating reactive oxygen species (ROS) is studied. The study shows that miRNA drives p53
dynamics at various states, namely, stabilized states and oscillating states (damped and sustain
oscillation). We found the co-existence of these states within certain range of the concentartion
level of miRNA in the system. This co-existence in p53 dynamics is the signature of the system’s
survival at various states, normal, activated and apoptosis driven by a constant concentration of
miRNA.
Introduction.− The p53, tumor suppressor protein,
attracted the interest of researchers because of its im-
portant role in preventing cell to become cancer [1, 2].
It acts as a key regulator in the cellular network and
response to a variety of cellular stress, including DNA
damage, hypoxia, nucleotide depletion, nitric oxide and
aberrant proliferative signals (such as oncogene activa-
tion) [1, 3]. But in most cases of human cancer cell, p53
tumor suppressor signaling pathway usually found in in-
activated condition [1]. Its activation results in the ful-
fillment of key cellular processes, for example, cell-cycle
arrest, senescence and most importantly tumor clearance
to prevent cancer cell formation [4]. Further, activated
p53 protein safeguards the organism against the prop-
agation of cells that carry damaged DNA with poten-
tially oncogenic mutations [3]. It has been reported that
activation of p53 functions via the inhibition of MDM2
protein can be regarded as an effective approach in can-
cer therapy [5]. Because MDM2 acts as a negative feed-
back regulator (inhibitor) to p53 by binding itself to p53,
and then physically blocking its ability to transactivate
gene expression, and stimulating its degradation [6–8].
Further, the interaction of N-terminal domain of MDM2
with transactivation domain of p53 (p53TAD) performs
a significant role in the regulation of the G1 checkpoint
of the cell cycle and cell function[9, 10].
ROS (Reactive oxygen species) are chemically reac-
tive molecules containing oxygen ions and peroxides[11].
They are synthesized from normal metabolism ofoxygen
as a natural byproduct and play important roles incell
signalingandhomeostasis [12, 13].However, ROS level in-
side cell can be elevated by UV irradiation or heat ex-
posure which can drive the cell at different stress states
[12]. High level of ROS can promote DNA damage, and
may probably lead the cell to mutagenesis, carcinogene-
sis and aging [11, 13, 14]. However, the role of ROS in
driving the cell at different states, namely, normal, stress,
cancerous and apoptosis is still not fully studied.
MicroRNAs (miRNAs) are small noncoding RNA
molecule of size 20-24 nucleotides, and are powerful reg-
ulators of transcriptional and post transcriptional gene
expression which regulate both physiological and patho-
logical processes such as cellular development and cancer
[15–17]. miR-125b is a brain-enriched miRNA which acts
as a negative regulator of p53 both in zebrafish and hu-
man [18–20]. Overexpression of miR-125b suppresses the
endogenous level of p53 protein and represses to apop-
tosis in human neuroblastoma cells and human lung fi-
broblast cells [20]. Decrease in level of miR-125b leads to
enhance the level of p53 and induces apoptosis in human
neuroblastoma and human lung fibroblast cells [18, 20].
However, the regulating mechanism of miR-125b with
p53 is not fully studied. The dynamics of p53 and its
response to the miR-125b regulation are still open ques-
tions. In the present study, we try to answer some of
these fundamental questions based on basic model built
from available experimental reports.
p53−MDM2−miRNA model.− The model we con-
sider (Fig. 1) is integration of p53-Mdm2 regulatory
network [21] with stress inducers ROS via DNA dam-
age [13] and miRNA which interact with p53 MDM2
[19]. In this model we asuume that miRNAs are sup-
posed to be constantly produced in the nucleus either
from their own genes or encode from introns (non-coding
sequence) with a rate k1 [19]. ROS synthesis is assumed
to occur with a rate of k14. This ROS synthesis trig-
gers DNA damage with a rate of k16 [13]. Then this
DNA damage leads to the activation of ARF with a
rate k18 [22] followed by the degradation of ARF with
a rate of k17. Further, the activated ARF protein binds
to MDM2 with a rate of k20 to control ubiquitination of
p53 [23]. The ARF and MDM2 interaction results into
to the formation of ARF MDM2 complex [24]. The for-
mation of ARF MDM2 complex reduces the concentra-
tion level of MDM2 in the systems which in turn alters
the behaviour of p53 [24]. On the other hand, disso-
ciation of ARF MDM2 complex with a rate k21 helps
the degradation of MDM2 population and recruit acti-
vated ARF. miRNA directly interacts with p53 mRNA
to form miRNA p53 mRNA complex at a rate k2 [17].
The ubiquitination of p53 mRNA is done via miRNA
which occurs with a rate k3 [19]. The synthesis of p53
takes place through transcription of p53 mRNA with a
rate k4. Further, this p53 synthesis depends on the avail-
2FIG. 1. A schematic diagram of p53-Mdm2-mi-RNA network
model.
able p53 mRNA concentration level. At normal condi-
tion p53 is generally bound to MDM2 with a rate k10
recruiting a complex p53 MDM2 and after which the dis-
sociation of the complex ubiquitinates p53 with a rate k11
andMDM2 with a rate k12 [25, 26] exhibiting oscillatory
behavior of p53 in the model. Further, p53 is found to
be transcription factor which interact with MDM2 gene
and leads to the production of MDM2 mRNA with a
rate k7 [21]. Hence, the MDM2 mRNA provides inter-
mediary link between p53 and MDM2. The self ubiqui-
tination of MDM2 mRNA is assumed to be with a rate
k9. MDM2 mRNA synthesize MDM2 protein with a
rate k8. The self ubiquitination of MDM2 is assumed
to be with a rate k13. The molecular species involved in
this model are listed in Table 1 (Supplementary file), and
the biochemical reaction channels involved in the model
network with their descriptions, kinetic laws and values
of the rate constants used in our simulations are given in
Table 2 (Supplementary file).
Consider the state of the system be described by a state
vector given by, x(t)=[x1(t), x2(t), . . . , xN (t)]
T
, where,
{x} is the set of concentrations of the respective molecu-
lar species, N = 11 and T is the transpose of the vector.
The model biochemical network (Fig. 1) described by the
twenty two reaction channels (Table 2) can be described
by the following coupled ordinary differential equations
(ODE) using Mass action law of chemical kinetics,
dxi(t)
dt
= Fi [x1(t), x2(t), . . . , xN (t)] (1)
where, i = 1, 2, ..., N and Fi is the ith function whose
form is given in Supplementary file. The non-linear cou-
pledN ODEs (1) (Supplementary fine) of p53−MDM2−
miRNA model are solved using 4th order Runge-Kutta
method which is the standard algorithm for numerical
integration [27] to find the dynamics of the system vari-
ables. The simulation is done for 10 days using the pa-
rameter values given in Supplementary file (Table 2) and
starting from an initial condition.
ROS driven p53 phase transition.− The concentra-
tion of ROS in the system drives the system dynamics
at different states which may correspond to various tem-
poral cellular states. The simulation is done first keeping
kmiRNA = 0 throughout the numerical experiment, and
changing the parameter kROS (Fig. 2). Since kROS is
the rate of creation of ROS, the concentration of ROS
synthesized in the system is proportional to kROS . The
p53 level in the system is maintained at stabilized state
with minimum concentration level for sufficiently small
values of kROS (kROS ≤ 0.00002) which may correspond
to normal state of the system. As the value of kROS
increases slightly (0.0002 ≤ kROS〈0.002) the dynamics
cross over from stable state to damped oscillation state
(Fig. 2 B) where the dynamics preserves stable condi-
tion for certain interval of time ([0-7] days), and then it
becomes activated (for time≥ 7 days) induced by kROS .
This result suggests that as the concentration of ROS
increases in the system, it causes more DNA damage due
to which p53 dynamics become stressed and exhibits an
oscillatory pattern. Further increase in the value of kROS
(0.002 ≤ kROS〈0.008) leads the p53 dynamics to damped
oscillation for some interval of time then to sustained os-
cillation with increasing amplitude (Fig. 2 C and D; Fig.
3 upper left panel). The sustain oscillation indicates that
the p53 is strongly activated (the stress is maximum).
Now, excess increase in ROS concentration (kROS ≥
0.015) drives the p53 dynamics from sustain to damped
oscillation (Fig. 2 E), after which p53 state is switched to
stabilized state (Fig. 2 E and F; Fig. 3 upper left panel).
This suggests that extreme values of kROS may cause
very high DNA damage, such that the damage could not
able be repaired back, which could be the condition of
apoptotic phase.
Role of miRNA on p53 dynamics.− The interaction
of miRNA with p53 is done via p53 mRNA complex
in indirect fashion. The impact of miRNA on p53 was
studied by keeping fixed kROS = 0.00005 and allowing
to change the values of kmiRNA (Fig. 2 right panels).
Similarly, as obtained in ROS case, we got three differ-
ent states namely stable, damped with sustain oscilla-
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FIG. 2. (A)The p53 temporal behaviour when ROS act as
a stress inducer whereas mi−RNA creation rate kept fixed.
(B)The p53 temporal behaviour when mi − RNA act as a
stress inducer whereas ROS creation rate kept fixed.
tion and again stable state of p53 driven by miRNA
(Fig. 2 right panels). The small values of kmiRNA
(kmiRNA〈0.000001) could not able to provide signifi-
cant stress to p53 dynamics, and maintains at stabilized
state (Fig. 2 A). The further increase in kmiRNA values
(0.00001 ≤ kmiRNA〈0.0002) the dynamics still maintains
stability upto certain interval of time (Fig. 2 B, C, D),
after which the dynamics is switched to damped oscil-
lation (weakly activated) for short interval of time and
then to sustain oscillation (strongly activated). Further
increase in kmiRNA compels the dynamics to stabilized
state again with low concentration level (Fig. 2 F). This
suggests that the increase in concentration of miRNA in
the system drives the system at various stress states, low-
ering p53 concentration level [20, 28]. The excess kmiRNA
values induce lowering of p53 concentration level even be-
low normal stabilized p53 state indicating the possibility
of switching stress state to cancerous state [28].
Co − existence of states.− The phase transition like
behaviour of the system dynamics induced by ROS and
miRNA concentrations available in the system can be
well characterized by analysing the nature of transition
time of the p53 dynamics. We define T1s to be the transi-
tion time below (t〈T1s) which the dynamics shows stable
state (does not show any oscillation) and above which the
dynamics shows oscillatory behaviour. We further define
second transition time, Tds which separates increasing
damped and sustain oscillations (Fig. 2). Similarly, Tsd
and T2s are taken as transition times separating sustain
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FIG. 3. A comparative plot for the amplitude verses kROS in
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FIG. 4. A phase diagram showing impact of kROS on stabil-
ity of p53 as well as impact of kmi−RNA on stability of p53
protein.
and damped oscillation, and damped oscillation and sta-
bilized state. We then calculated T1s, Tds, Tsd and T2s
as a function of kROS (Fig. 4 upper panel) where the
regimes for T 〈T1s and T 〉T2s corresponds to stabilized
states, regimes between Tds〉T 〉T1s and T2s〉T 〉Tsd cor-
responds to damped states and Tsd〉T 〉Tds indicates the
sustain oscillation state regime.
The results indicate that there is a certain range of
kROS (region bounded by two lines) where one can find
the four states together including two stable states for
4any value of kROS (Fig. 4 upper panel). This means
that for any concentration of ROS in the system cor-
responding to any values within this range, the p53 dy-
namics will stay stable for some interval of time, then it
will start activated to reach maximum activation within
certain interval of time and after sometime it will stay
stable again. In the other regimes, at most we can find
three states.
Similarly, the co-existence of the four states can be ob-
tained in the case of miRNA induced p53 dynamics also.
Within this co-existence regime, the regions of damped,
sustain and stabilized states are different as compared
to ROS induced p53 dynamics. This co-existence of the
states indicate that exposure of the system to constant
miRNA concentration can drive the system from normal
to stress and then to apoptosis.
Conclusion.− p53 is found to be a versatile protein
which can interact with a number of protein and partici-
pate in many biologically important pathway. There are
a number of factors which can induce cellular stress, such
as environmental factors (UV, IR etc), stress inducing
molecules (ROS, miRNA, nitric oxide and many other
molecules). The variation in concentration of reactive
oxygen species in cellular system leads to the changes
in the p53 dynamics (various stress states) with over-
all enhancement in its concentration level in the cell.
Further, the introduction miRNA 125b to the system
shows inhibitory effect on p53 production and switching
of stress states by varying miRNA 125b concentration
[18, 20]. The obtained results are quite interesting and
provide many hidden information regading the activity of
miRNA 125b that it can probably switch the system to
cancerous state. Various experimental studies reported
that concentration of miRNA 125b increases in different
cancer cell lines especially in breast cancer, leukemia and
uterus cancer cell lines. Therefore, it is very important
to study miRNA in depth in order to understand other
roles of it in regulating cancerous cells.
Our study shows that significant activity of miRNA
can be seen only when the the system is slightly activated
by ROS but this process is not needed to study ROS ac-
tivity. This means that there is always a competition
between ROS and miRNA which is needed to be inves-
tigated extensively. Moreover, the impact of the miRNA
on p53 regulatory pathway should be further studied in
stochastic system in order to capture the state switching
mechanism quantitatively and to understand the role of
noise in the cellular process.
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The model biochemical network (Fig. 1) described
by the twenty two reaction channels (Table 2) can be
described by the following coupled ordinary differential
equations (ODE) using Mass action law of chemical ki-
netics,
dx1
dt
= k4x4 − k10x1x2 + k12x5 (1)
dx2
dt
= k8x3 − k10x1x2 + k11x5 + k12x5 − k13x2 − k20x2x8(2)
dx3
dt
= k7x1 − k9x3 (3)
dx4
dt
= −k2x10x4 + k5 − k6x4 (4)
dx5
dt
= k10x2x1 − k11x5 − k12x5 (5)
dx6
dt
= k14 − k15x6 − k16x6 (6)
dx7
dt
= k16x6 − k17x7 (7)
dx8
dt
= k18x7 − k19x8 − k20x8x2 + k21x9 (8)
dx9
dt
= k20x8x2 − k21x9 (9)
dx10
dt
= k1 − k2x10x4 + k3x11 − k22x10 (10)
dx11
dt
= k2x10x4 − k3x11 (11)
The set of ODEs can be written in compact form as in
the following,
dx(t)
dt
= F(x1, x2, . . . , xN ) (12)
where, F = [F1, F2, . . . , FN ]
T
is the functional vector.
The time evolution of the state vector ~x(t) can be ob-
tained by numerically solving the non-linear coupled
differential equations (1)-(11) using standard 4th order
Runge-Kutta algorithm for numerical integration [27].
Stability analysis
The fixed or equilibrium points of the ODE given by
equation (12) can be obtained by putting dx(t)dt = 0 and
solving for x∗1, x
∗
2, ..., x
∗
N from these equations. In our
model described by mathematical equations (1)-(11), we
have the following equilibrium points,
x∗1 =
[
k4k5k9
k7k8k10k11
{
k13 +
kROSk16k18k20
k17k18(k15 + k16)
}
k11 + k12
k6 +
k2
k22
kmiRNA
]1/2
(13)
x∗2 =

 k4k5k7k8(k11 + k12)
k9k10k11
{
k13 +
kROSk16k18k20
k17k18(k15+k16)
} 1
k6 +
k2
k22
kmiRNA


1/2
(14)
x∗3 =
[
k4k5
k8k10k11
{
k13 +
kROSk16k18k20
k17k18(k15 + k16)
}
k11 + k12
k6 +
k2
k22
kmiRNA
]1/2
(15)
x∗4 =
k5k22
k2 + k1k6
(16)
x∗5 =
k4k5k22
k11(k2 + k1k6)
(17)
x∗6 =
kROS
k15 + k16
(18)
x∗7 =
kROSk16
k17(k15 + k16)
(19)
x∗8 =
kROSk16k18
k17k19(k15 + k16)
(20)
x∗9 =

 k4k5k7k8(k11 + k12)
k9k10k11
{
k13 +
kROSk16k18k20
k17k18(k15+k16)
} 1
k6 +
k2
k22
kmiRNA


1/2
× kROSk16k18k20
k17k19k21(k15 + k16)
(21)
x∗10 =
k1
k22
(22)
x∗11 =
k1k2k5
k3(k2 + k1k6)
(23)
The stabilized state of p53 (x∗1) and Mdm2 (x
∗
2) are de-
pendent on the values of the parameters kmiRNA and
kROS , and there is competition between these two param-
eters affecting stabilized states of p53 and Mdm2. Keep-
ing kmiRNA to a constant value, equation (13) shows that
x∗1 ∝
√
1 +AkROS , where, A =
k16k18k20
k13k17k18(k15+k16)
which
drives the low equilibrium state (may be normal state
where x∗1 is maintained minimum value) at low kROS
to the higher equilibrium state (may be apoptosis state
where x∗1 is maintained at high value) as kROS increases.
However, in the case of Mdm2, the scenario is oppo-
site, where x∗2 ∝ 1√1+AkROS , and kROS drives the higher
Mdm2 equilibrium state to lower equilibrium state.
Further, if kROS and other rates are kept constant,
x∗1 ∝ 1√B+kmiRNA and x
∗
2 ∝ 1√B+kmiRNA , where B is a
2constant given by B = k6k22k2 . This means that as kmiRNA
increases, kmiRNA drives the higher equilibrium state of
both p53 and Mdm2 to lower equilibrium states.
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3Table 1 - List of molecular species
S.No. Species Name Description Notation
1. p53 Unbounded p53 protein x1
2. Mdm2 Unbounded Mdm2 protein x2
3. Mdm2 mRNA Mdm2 messenger mRNA x3
4. p53 mRNA p53 messenger mRNA x4
5. Mdm2 p53 Mdm2 with p53 complex x5
6. ROS Reactive Oxygen Species x6
7. Dam DNA Damage DNA x7
8. ARF Alternative Reading Frame protein x8
9. ARF Mdm2 ARF and Mdm2 complex x9
10. mi−RNA− 125b Micro RNA 125b x10
11. mi−RNA p53−mRNA Micro RNA 125b and p53 mRNA
complex
x11
Table 2 List of chemical reaction, Kinetic Laws and their rate constant
S.No Reaction Name of the process Kinetic Law Rate Constant References
1 φ
k1−→ x10 Micro RNA creation k2 1× 10
−4sec−1 [16, 19, 20]
2 x10 + x4
k2−→ x11 Synthesis of miRNA and
p53 mRNA complex
k2〈x10〉〈x4〉 2× 10
−2sec−1 [16, 20]
3 x11
k3−→ x10 miRNA p53 mRNA degra-
dation
k3〈x11〉 1× 10
−4sec−1 [16, 20]
4 x4
k4−→ x1 + x4 p53 mRNA translation k4〈x4〉 8× 10
−2sec−1 [3, 21]
5 φ
k5−→ x4 p53 mRNA synthesis k5 1× 10
−3sec−1 [3, 21]
6 x4
k6−→ φ p53 mRNA degradation k6〈x4〉 1× 10
−4sec−1 [3, 21]
7 x1
k7−→ x1 + x3 Mdm2 mRNA synthesis k7〈x1〉 1× 10
−4sec−1 [3, 21, 26]
8 x3
k8−→ x2 + x3 Mdm2 synthesis k8〈x3〉 495× 10
−5sec−1 [3, 21, 26]
9 x3
k9−→ φ Mdm2 mRNA degradation k9〈x3〉 1× 10
−4sec−1 [3, 21, 26]
10 x1 + x2
k10−→ x5 p53 Mdm2 complex forma-
tion
k10〈x1〉〈x2〉 1155 × 10
−3sec−1 [3, 21, 26]
11 x5
k11−→ x2 Mdm2 creation k11〈x5〉 825× 10
−4sec−1 [3, 21, 26]
12 x5
k12−→ x1 + x2 Dissociation of p53 Mdm2
complex
k12〈x5〉 1155 × 10
−5sec−1 [3, 21, 26]
13 x2
k13−→ φ Mdm2 degradation k13〈x2〉 433× 10
−4sec−1 [3, 21, 26]
14 φ
k14−→ x6 ROS formation k14 1.0× 10
−2sec−1 [14, 21]
15 x6
k15−→ φ Degradation of ROS k15〈x6〉 2× 10
−2sec−1 [14, 21]
16 x6
k16−→ x7 Initiation of DNA damage k16〈x6〉 2× 10
−2sec−1 [14, 21]
17 x7
k17−→ φ DNA repair k17〈x7〉 2× 10
−5sec−1 [14, 21]
18 x7
k18−→ x8 + x7 Activation of ARF k18〈x7〉 33× 10
−5sec−1 [21, 23, 24]
19 x8
k19−→ φ Degradation of ARF k19〈x8〉 1× 10
−4sec−1 [21, 23, 24]
20 x8 + x2
k20−→ x9 ARF Mdm2 complex for-
mation
k20〈x8〉〈x2〉 1× 10
−2sec−1 [21, 23, 24]
21 x9
k21−→ x8 Dissociation of ARF Mdm2
complex
k21〈x9〉 1× 10
−3sec−1 [21, 23, 24]
22 x10
k22−→ φ Degradation of Micro RNA k22〈x10〉 5× 10
−2sec−1 [16, 19]
